Kazia Therapeutics (KZIA) Short term Debt (2018 - 2025)

Kazia Therapeutics (KZIA) has disclosed Short term Debt for 5 consecutive years, with $2.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Short term Debt rose 382.83% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Jun 2025, up 382.83%, and an annual FY2025 reading of $2.0 million, up 391.0% over the prior year.
  • Short term Debt was $2.0 million for Q2 2025 at Kazia Therapeutics, up from $417821.5 in the prior quarter.
  • Across five years, Short term Debt topped out at $2.0 million in Q2 2025 and bottomed at -$1.3 million in Q2 2022.
  • Average Short term Debt over 4 years is $579227.9, with a median of $809098.4 recorded in 2023.
  • The sharpest move saw Short term Debt crashed 65.19% in 2024, then surged 382.83% in 2025.
  • Year by year, Short term Debt stood at -$1.3 million in 2022, then surged by 191.03% to $1.2 million in 2023, then plummeted by 65.19% to $417821.5 in 2024, then soared by 382.83% to $2.0 million in 2025.
  • Business Quant data shows Short term Debt for KZIA at $2.0 million in Q2 2025, $417821.5 in Q2 2024, and $1.2 million in Q2 2023.